![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » GENAERA ENROLLS FIRST PATIENT IN EVIZON TRIAL
GENAERA ENROLLS FIRST PATIENT IN EVIZON TRIAL
June 26, 2006
Genaera has reported that the first patient has been enrolled in a multicenter, open-label, pharmacodynamic Phase II clinical trial to explore the efficacy and safety of Evizon at higher doses.
The study is designed to evaluate up to 140 patients with wet age-related macular degeneration treated with Evizon at four dose levels over a 20 week period.
Evizon is a product, in development for ophthalmic indications, specifically wet age-related macular degeneration.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct